Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
35 results about "Therapy Outcome" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Therapy Outcomes. Within the field of speech-language pathology and even among those who stutter, there is disagreement about acceptable treatment outcomes from stuttering therapy. Some believe the only acceptable therapy outcome is a significant reduction in or total elimination of stuttering.
Selective nerve stimulation with optionally closed-loop capabilities
ActiveUS20080234780A1Extend battery lifeMaximize efficacyInternal electrodesExternal electrodesSide effectMedicine
Systems and methods for steering one or more stimulation fields to a selected nerve target, thereby optimizing one or a combination of low stimulation thresholds, desired therapy outcomes, or a minimization of adverse stimulation side-effects. An array of electrodes disposed, at least in part, on two or more neural stimulation leads are used for steering the stimulation fields to the selected nerve target and are positioned adjacent the selected target. The stimulation may be titrated based on, among other things, a detected physiologic response to the applied stimulation.
Owner:CARDIAC PACEMAKERS INC
Method and System for Patient Specific Planning of Cardiac Therapies on Preoperative Clinical Data and Medical Images
ActiveUS20130197881A1Increase the number ofEasy to placeUltrasonic/sonic/infrasonic diagnosticsMedical imagingSonificationBiomechanics
A method and system for patient-specific planning of cardiac therapy, such as cardiac resynchronization therapy (CRT), based on preoperative clinical data and medical images, such as ECG data, magnetic resonance imaging (MRI) data, and ultrasound data, is disclosed. A patient-specific anatomical model of the left and right ventricles is generated from medical image data of a patient. A patient-specific computational heart model, which comprises cardiac electrophysiology, biomechanics and hemodynamics, is generated based on the patient-specific anatomical model of the left and right ventricles and clinical data. Simulations of cardiac therapies, such as CRT at one or more anatomical locations are performed using the patient-specific computational heart model. Changes in clinical cardiac parameters are then computed from the patient-specific model, constituting predictors of therapy outcome useful for therapy planning and optimization.
Owner:SIEMENS HEATHCARE GMBH
Prognostic and diagnostic method for cancer therapy
InactiveUS20090170715A1Sugar derivativesMicrobiological testing/measurementTherapy resistantCancers diagnosis
The present invention provides novel methods and kits for diagnosing the presence of cancer within a patient, and for determining whether a subject who has cancer is susceptible to different types of treatment regimens. The cancers to be tested include, but are not limited to, prostate, breast, lung, gastric, ovarian, bladder, lymphoma, mesothelioma, medulloblastoma, glioma, and AML. Identification of therapy-resistant patients early in their treatment regimen can lead to a change in therapy in order to achieve a more successful outcome. One embodiment of the present invention is directed to a method for diagnosing cancer or predicting cancer-therapy outcome by detecting the expression levels of multiple markers in the same cell at the same time, and scoring their expression as being above a certain threshold, wherein the markers are from a particular pathway related to cancer, with the score being indicative or a cancer diagnosis or a prognosis for cancer-therapy failure. This method can be used to diagnose cancer or predict cancer-therapy outcomes for a variety of cancers. The markers can come from any pathway involved in the regulation of cancer, including specifically the PcG pathway and the “stemness” pathway. The markers can be mRNA, microRNA, DNA, or protein.
Owner:ORDWAY RES INST
NANO46 Genes and Methods to Predict Breast Cancer Outcome
InactiveUS20130337444A1Low and high riskSugar derivativesMicrobiological testing/measurementTherapy OutcomePolymerase chain reaction
The present invention provides methods for classifying and for evaluating the prognosis of a subject having breast cancer are provided. The methods include prediction of breast cancer subtype using a supervised algorithm trained to stratify subjects on the basis of breast cancer intrinsic subtype. The prediction model is based on the gene expression profile of the intrinsic genes listed in Table 1. Further provided are compositions and methods for predicting outcome or response to therapy of a subject diagnosed with or suspected of having breast cancer. These methods are useful for guiding or determining treatment options for a subject afflicted with breast cancer. Methods of the invention further include means for evaluating gene expression profiles, including microarrays and quantitative polymerase chain reaction assays, as well as kits comprising reagents for practicing the methods of the invention.
Owner:UNIV OF UTAH RES FOUND +4
Fully Automated Health Plan Administrator
InactiveUS20070250352A1Improve medical qualityAccurate and Rapid DiagnosisFinanceHealth-index calculationIntensive care medicineMedical treatment
A system for administering a health care system, comprising up to five processing means and a database. The system accepts inputs from enrollees, insureds, providers, insurers and vendors, but requires no input from an administrator. The apparatus optionally includes devices for: measuring patient treatment outcomes, a “just-in-time” appointment rescheduler, an editable archive of prototypical treatment plans, measuring the diagnostic accuracy of diagnosing physicians and measuring the complication rate of treatment providers.
Owner:TAWIL JACK J
Identification of genetic alterations that modulate drug sensitivity in cancer treatments
InactiveUS20080242622A1Improve efficiencyModulate cancer cells' sensitivity to an anti-cancer drugBiocideLibrary screeningCancer cellDrugs sensitivity
Owner:COLD SPRING HARBOR LAB INC
Prognostic and diagnostic method for disease therapy
Owner:ORDWAY RES INST
Simultaneous Delivery of Receptors and/or Co-Receptors for Growth Factor Stability and Activity
InactiveUS20090220588A1Reduce capacityPeptide/protein ingredientsPeptide preparation methodsFactor iiCo delivery
The compositions and methods of the present invention relate to the co-delivery of a molecule and a polypeptide to cells to improve the therapeutic efficacy of the molecules. In one embodiment of the invention, the invention may improve delivery of growth factors by co-delivering these growth factors with their receptors and co-receptors, such as syndecans. Co-delivery of growth factors with syndecans, for example, may protect growth factors from proteolysis, enhance their activity, and target the growth factors to the cell surface to facilitate growth factor signaling. This novel approach to growth factor therapy could be extended to other systems and growth factors enabling the enhancement of multiple signaling pathways to achieve a desired therapeutic outcome.
Owner:MASSACHUSETTS INST OF TECH
Methods for Predicting Treatment Response Based On the Expression Profiles of Protein and Transcription Biomarkers
InactiveUS20090304594A1Improve predictive performanceOptimize timingMicrobiological testing/measurementDisease diagnosisADAMTS ProteinsBiomarker (petroleum)
The invention disclosed herein describes novel biomarkers useful for risk assessment, screening, prognosis and selection and monitoring of therapy for HDAC mediated cell proliferative disorders. In particular, the invention provides the identities of three particular proteins whose expression patterns are strongly predictive of a particular patient's treatment outcome, e.g., non-responsiveness to SAHA. The expression profile, or pattern, whether embodied in nucleic acid expression, protein expression, or other expression formats will find use in identifying and selecting patients afflicted with a particular HDAC mediated cancer who are likely to be non-responsive to SAHA-based therapy and thus candidates for other treatments.
Owner:MERCK SHARP & DOHME CORP
Method for building pathogenetic condition assessment model of ICU patient and server
ActiveCN107436993AReliable predictionSpecial data processing applicationsFeature vectorFeature extraction
The invention provides a method for building a pathogenetic condition assessment model of an ICU patient and a server. The method comprises the steps that vital sign data and treatment results of historical ICU patients are obtained; the vital sign data is subjected to feature extraction, and corresponding feature vectors are obtained; according to the feature vectors, an analysis model between the feature vectors and the treatment results are trained, wherein the analysis model is used for assessing the treatment result of the current patient according to the real-time vital sign data of the current ICU patient. By means of the analysis model and the vital sign data of the current ICU patient, the treatment result is assessed so that the treatment result can be reliably predicted.
Owner:陈一昕
System for diagnostic and treatment of physical and cognitive capabilities
InactiveUS20160256771A1Improve the quality of lifeLow costPhysical therapies and activitiesData processing applicationsCaregiver personCognitive capability
In one illustrative embodiment, a tele-rehabilitation platform allows patients to play and interact with therapists, caregivers, and other patients. The platform includes a set of computer games, a therapist portal, and a knowledgebase for the storage and analysis of therapy outcomes for specific patients, conditions, and therapy regimes.
Owner:INDIANA UNIV RES & TECH CORP +1
Methods of using zonisamide as an adjunctive therapy for partial seizures
Methods of using zonisamide as an adjunctive therapy for partial seizures are disclosed. In particular, the methods enhance the safety of patients taking pharmaceutical formulations of zonisamide by providing information that increases the awareness of rhabdomyolysis and / or elevated CPK as possible side effects; wherein the patients and / or prescribing physicians and other medical care providers are advised to monitor for such conditions and employ methods that will improve the therapeutic outcome in the few patients who experience rhabdomyolysis and / or elevated CPK associated with zonisamide therapy.
Owner:EISAI INC
Antigenic targets of autoimmune sensorineural hearing loss (AISNHL) and development of tests for diagnosis and management of AISNHL
InactiveUS20030082646A1Organic active ingredientsPeptide/protein ingredientsTherapy OutcomeSupporting cell
This invention relates generally to antigens reactive with autoantibodies associated with autoimmune sensorineural hearing loss (AISNHL), and in particular relates to a novel antigen, Inner Ear Supporting Cell Antigen (IESCA) reactive with autoantibodies associated with autoimmune sensorineural hearing loss (AISNHL), and to methods for the detecting therapeutic outcomes in treatment of AISNHL patients, and to methods of detecting genetic lesions in genes encoding for such antigens.
Owner:THE RGT OF THE UNIV OF MICHIGAN
Fully automated health plan administrator
InactiveUS8165894B2Easy to compareQuality improvementFinanceHealth-index calculationQuality adjustmentAutomated method
A system for fully automating the administration of a health plan. The system accepts inputs from enrollees, insureds, providers, insurers and vendors, but requires no physical data entry from the plan administrator. The system also features an automated methodology that measures patient treatment outcomes in terms of quality-adjusted life-years, by diagnosis and by medical treatment provider. The system also includes automated methods for: a “just-in-time” appointment scheduler, an editable archive of prototypical treatment plans, measuring the diagnostic accuracy of diagnostic physicians and for measuring the complication rate of treatment providers.
Owner:TAWIL JACK J
Methods of using zonisamide as an adjunctive therapy for partial seizures
Methods of using zonisamide as an adjunctive therapy for partial seizures are disclosed. In particular, the methods enhance the safety of patients taking pharmaceutical formulations of zonisamide by providing information that increases the awareness of hyperammonemia as a possible side effect; wherein the patients and / or prescribing physicians and other medical care providers are advised to monitor for hyperammonemia and employ methods that will improve the therapeutic outcome in the few patients who experience hyperammonemia associated with zonisamide therapy.
Owner:EISAI INC
Methods and kits to predict prognostic and therapeutic outcome in small cell lung cancer
InactiveUS20110171323A1The test effect is goodEasy to identifyHeavy metal active ingredientsBiocideSystemic chemotherapyMedicine
Disclosed herein are methods used in the identification of cancer patients likely or unlikely to respond to systemic chemotherapy, methods of treating cancer patients based upon the identification, and kits that facilitate the identification. The methods and kits involve detecting the expression of specific microRNA.
Owner:TRANSLATIONAL GENOMICS RESEARCH INSTITUTE +1
Therapeutic exercise method and therapeutic exercise apparatus
ActiveUS20140342877A1Add function optionsIncrease motivationFreely-suspended gymnasticsChiropractic devicesPhysical medicine and rehabilitationMonitoring and control
The proposed apparatus and method relate to restorative sports medicine and patient rehabilitation with neurological motoric disorders. A patient is positioned in equilibrium by suspension devices for patient's body parts. The suspension devices are moved by actuating mechanisms with an electro-pneumatic drive and actuating components, controlled by a programmed computer, motivating the patient by controlling an object in a virtual gaming environment, to restore movements when there is an initially minimal or a complete absence of physical activity. The effectiveness is judged according to the reduction of energy consumption of the drives. The apparatus includes a base composed of two parallel guides with movable crossbars, on which the actuating mechanisms are pairwise movably arranged, monitoring and control units, the computer, sensors detecting the state of the actuating mechanisms, and power sources. There are units for analyzing the energy consumption of each drive and for assessing the treatment results.
Owner:KRISAF LLC
Monitoring immunotherapy of lewy body disease from constipation symptoms
The invention provides methods of monitoring immunotherapy directed against alpha-synuclein by comparing a subject's constipation symptoms before treatment and at one or more times during and / or after treatment. The immunotherapeutic regime can be monitored depending on the results of treatment.
Owner:PROTHENA BIOSCI LTD
Methods of evaluating response to cancer therapy
InactiveUS20150376710A1Mechanical/radiation/invasive therapiesLibrary screeningOncologyCancer therapy
Owner:NUVERA BIOSCI +1
Identification of novel subgroups of high-risk pediatric precursor b acute lymphoblastic leukemia, outcome correlations and diagnostic and therapeutic methods related to same
ActiveUS20110045999A1High riskMicrobiological testing/measurementLibrary screeningOncologyTherapy Outcome
The present invention relates to the identification of genetic markers patients with high risk B-precursor acute lymphoblastic leukemia (B-ALL) and associated methods and their relationship to therapeutic outcome. The present invention also relates to diagnostic, prognostic and related methods using these genetic markers, as well as kits which provide microchips and / or immunoreagents for performing analysis on leukemia patients.
Owner:STC UNM +1
Methods to predict the outcome of treatment with antidepressant medication
The invention provides a method for determining the outcome of treatment with an antidepressant medication in a patient. In particular, the invention provides a method of screening patients to identify those patients with a decreased risk of non-response to treatment with antidepressant medication by obtaining a sample of genetic material from the patients, and then assaying the sample for the presence of a genotype which is associated with a decreased risk of non-response to treatment with antidepressant medication. The genotype is characterized by a polymorphism in the genes HTR2A, GRIK4, BCL2, and a combination thereof.
Owner:GOVERNMENT OF THE US REPRESENTED BY THE SEC +1
Activities and ph tests for the determination of the risk of obstetric and gynecologic complications
The present invention provides a method for selecting a specific population of women at risk of developing an obstetric or gynecological condition, the risk being expressed by an odds ratio (OR) value higher than 5.5, the method comprising the following steps in sequence: a) passing Determination of sialidase levels in body fluid samples by the method described by Cauci et al. in Am. J. Obstet. Gynecol. 1998; vol. 178; p511-5, and / or, by Cauci et al. in J. Infect. Dis.1998; vol.178; method described in p1698-706, to determine the activity of aminoacyl proline dipeptidase in a body fluid sample; b) determine the pH value of the body fluid sample; c) select a value with sialidase Samples with equal or higher than 5.0 nmol methoxyphenol and / or aminoacyl proline dipeptidase levels equal to or higher than 1500 mOD and pH ≥ 5.0. Thus, this approach provides physicians with an effective tool in deciding whether to administer drug therapy to women at risk of serious adverse outcomes.
Owner:UNIBIO CORP
Chronic insomnia remote cognitive-behavioural therapy system
InactiveCN104644128ARealize personalized remote non-drug treatment planShorten the timeDiagnostic recording/measuringSensorsTherapy monitoringThe Internet
The invention discloses a chronic insomnia (CI) remote cognitive-behavioural therapy system. The system comprises at least one patient mobile terminal; the patient mobile terminal is connected with a central workstation by internet; the central workstation is connected with at least one doctor mobile terminal by the internet. The patient mobile terminal comprises a patient mobile communication platform comprising a communication module I, an inspection conclusion import module, a standard interview module, a therapeutic schedule export module and an individualized prescription module; the central workstation comprises a server and a personal computer; the server comprises an optimizing module, a communication module II and a storage module; the doctor mobile terminal comprises a communication module III, a therapeutic schedule module, a therapy monitoring module and a therapy result analysis module. The cognitive-behavioural therapy basic interview is standardized by using the internet technology, the long-distance persistent CI cognitive-behavioural therapy is realized, and more CI patients are treated under limited medical resources.
Owner:中国人民解放军陆军特色医学中心 +1
Compositions and methods for cancer gene discovery
The present invention features transgenic non-human mammalian animals being genetically modified to develop cancer. The invention also relates to methods for identifying genes or genetic elements that are potentially related to human cancers using an chromosomally unstable animal model. Information on such genetic alterations can be used to predict cancer therapeutic outcomes and to stratify patient populations to maximize therapeutic efficacy.
Owner:DANA FARBER CANCER INST INC
Intelligent feedback type music relaxation hypnotic therapy system and implementation method
InactiveCN110141756ATime to playGrasp in placeEvaluation of blood vesselsRespiratory organ evaluationComputer moduleTherapeutic effect
The invention discloses an intelligent feedback type music relaxation hypnotic therapy system and an implementation method. The intelligent feedback type music relaxation hypnotic therapy system comprises a state monitoring module, an automatic playing module, a language hinting module, a treatment feedback module and a display module, wherein the state monitoring module comprises heart rate monitoring, respiration monitoring, limb movement monitoring and blood pressure monitoring; the automatic playing module comprises intelligent song selecting, artificial song selecting and a pre-set playing list; the language hinting module comprises a pre-set language base, a player, background replacement and atmosphere selection; and the treatment feedback module comprises a treatment result, a treatment problem and a solution. According to the intelligent feedback type music relaxation hypnotic therapy system disclosed by the invention, through monitoring respects related to body movement and mood of a curee, the system can automatically play music to enable the curee to relax and play hinting languages to achieve the treatment effects, and the technical requirements are reduced; besides, the playing opportunity of the music and hinting languages can be mastered in place, and the problem that a traditional manner is subjected to the influence of the experience of a curer, and the effectis unstable is solved.
Owner:QINGDAO TECHNOLOGICAL UNIVERSITY
Diagnosis and treatment of brain tumors
InactiveUS20130230453A1Reduce spreadReduces production and activityOrganic active ingredientsPeptide/protein ingredientsCancer preventionBrain tumor
The present invention relates to methods for the localisation, diagnosis, prognosis and / or prediction of therapeutic outcome of cancer, as well as methods for treating or preventing cancer. In particular, the present invention relates to methods for the localisation, diagnosis, prognosis and / or prediction of therapeutic outcome of brain tumors expressing calcitonin receptor, as well as the treatment and prevention of brain tumors by targeting calcitonin receptor expressing brain tumour cells.
Owner:WELCOME RECEPTOR ANTIBODIES
Display and method for medical procedure selection
InactiveCN101400298AChoose to helpData processing applicationsMedical automated diagnosisDisplay deviceComputer science
A display system and method for displaying information to a clinician when selecting the next appropriate diagnostic test or therapeutic procedure to order for a patient are provided. The system assists the clinician in selecting the next step based on the information the clinician hopes to gain from the test or the result of the treatment. The system will present general and patient-specific information about the procedure to assist the clinician's selection. The system includes a user interface configured for entering desired resultant information of a procedure; a processor configured to determine at least one result code from the entered desired resultant information from a database associating result codes to resultant information; the processor configured to determine at least one procedure matching the at least one result code; and a display device for presenting the determined at least one procedure.
Owner:KONINKLIJKE PHILIPS ELECTRONICS NV
Antigenic Targets Of Autoimmune Sensorineural Hearing Loss (AISNHL) And Development Of Tests For Diagnosis And Management Of AISNHL
InactiveUS20090075268A1Organic active ingredientsPeptide/protein ingredientsAntigenNeural hearing loss
This invention relates generally to antigens reactive with autoantibodies associated with autoimmune sensorineural hearing loss (AISNHL), and in particular relates to a novel antigen, Inner Ear Supporting Cell Antigen (IESCA) reactive with autoantibodies associated with autoimmune sensorineural hearing loss (AISNHL), and to methods for the detecting therapeutic outcomes in treatment of AISNHL patients, and to methods of detecting genetic lesions in genes encoding for such antigens.
Owner:RGT UNIV OF MICHIGAN
Therapeutic exercise method and therapeutic exercise apparatus
ActiveUS9662539B2Add function optionsRaising motivation and effectivenessMassage combsMassage beltsTherapeutic exercisePhysical medicine and rehabilitation
The proposed apparatus and method relate to restorative sports medicine and patient rehabilitation with neurological motoric disorders. A patient is positioned in equilibrium by suspension devices for patient's body parts. The suspension devices are moved by actuating mechanisms with an electro-pneumatic drive and actuating components, controlled by a programmed computer, motivating the patient by controlling an object in a virtual gaming environment, to restore movements when there is an initially minimal or a complete absence of physical activity. The effectiveness is judged according to the reduction of energy consumption of the drives. The apparatus includes a base composed of two parallel guides with movable crossbars, on which the actuating mechanisms are pairwise movably arranged, monitoring and control units, the computer, sensors detecting the state of the actuating mechanisms, and power sources. There are units for analyzing the energy consumption of each drive and for assessing the treatment results.
Owner:KRISAF LLC
Fast assignment of adequate chemotherapy with latinum based drugs for cancer patients based on the identification of constitutional brcal mutations
InactiveUS20110245095A1Difficult to accessLow costNucleotide librariesMicrobiological testing/measurementGenotypeBrucella
A new method to improve therapy outcome depending on a particular constitutional genotype have been disclosed. Subject of invention allows to synthesize DNA and identification of germline BRCA1 genetic abnormalities which are correlated with a significantly increased clinical response to chemotherapy based on platinum derived drugs in cancer patients.
Owner:POMORSKA ACAD MEDYCZNA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com